Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lansoprazole + domperidone is a fixed-dose combination of two pharmaceutical agents used primarily to treat gastrointestinal conditions such as gastroesophageal reflux disease (GERD), peptic ulcer disease, gastritis, and Zollinger-Ellison syndrome. Lansoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system in the stomach lining. Domperidone is a prokinetic agent that enhances gastrointestinal motility by antagonizing dopamine receptors in the gut, thereby increasing movement of food through the stomach and intestines and reducing symptoms like nausea and vomiting. The combination provides both acid suppression (from lansoprazole) and improved gastric emptying/antiemetic effects (from domperidone), offering symptomatic relief from heartburn, indigestion, bloating, nausea, vomiting, and related complications[1][4][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lansoprazole + domperidone.